Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. The Company's lead product includes EXPAREL, is a non-opioid local analgesic indicated for administration into the surgical site to produce postsurgical analgesia. EXPAREL combines bupivacaine with the DepoFoam to provide postsurgical pain control with a single intraoperative infiltration.


Company Growth (employees)
Type
Public
HQ
Parsippany Troy Hills, US
Founded
2006
Size (employees)
503 (est)
Website
pacira.com
Pacira Pharmaceuticals was founded in 2006 and is headquartered in Parsippany-Troy Hills, US

Pacira Pharmaceuticals Office Locations

Pacira Pharmaceuticals has offices in Parsippany-Troy Hills, San Diego and Jersey
Parsippany-Troy Hills, US (HQ)
5 Sylvan Way
San Diego, US
10578 Science Center Dr, Suite 125
San Diego, US
11011 N Torrey Pines Rd

Pacira Pharmaceuticals Data and Metrics

Pacira Pharmaceuticals Financial Metrics

Pacira Pharmaceuticals's revenue was reported to be $69.3 m in Q1, 2017
USD

Revenue (Q1, 2017)

69.3 m

Gross profit (Q1, 2017)

44.7 m

Gross profit margin (Q1, 2017), %

65%

Net income (Q1, 2017)

(19.9 m)

EBIT (Q1, 2017)

(14.1 m)

Market capitalization (17-Aug-2017)

1.4 b

Cash (31-Mar-2017)

109 m
Pacira Pharmaceuticals's current market capitalization is $1.4 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

85.6 m197.7 m249 m276.4 m

Revenue growth, %

131%26%11%

Cost of goods sold

54.8 m77.4 m71.8 m77.4 m

Gross profit

30.8 m120.2 m177.2 m198.9 m

Gross profit Margin, %

36%61%71%72%

R&D expense

18.7 m

General and administrative expense

106.7 m

Operating expense total

138.8 m202.8 m239.5 m202.8 m

EBIT

(53.3 m)(5.2 m)9.5 m(5.2 m)

EBIT margin, %

(62%)(3%)4%(2%)

Interest expense

7.3 m8.3 m7.7 m8.3 m

Interest income

259 k382 k678 k382 k

Pre tax profit

(64.4 m)(13.5 m)2.1 m(13.5 m)

Income tax expense

442 k(173 k)(264 k)(173 k)

Net Income

(63.9 m)(13.7 m)1.9 m(37.9 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

47.2 m52 m58.3 m59.1 m62.2 m65.5 m69.6 m68.4 m69.3 m

Cost of goods sold

20 m20.4 m17.6 m18.9 m15.9 m20.3 m23.1 m43.2 m24.6 m

Gross profit

27.2 m31.7 m40.7 m40.2 m46.3 m45.2 m46.6 m25.2 m44.7 m

Gross profit Margin, %

58%61%70%68%74%69%67%37%65%

R&D expense

5.2 m4.4 m6 m3.6 m5.9 m9.5 m9.4 m9.8 m16.6 m

General and administrative expense

24.8 m28.2 m31.4 m34.8 m35.3 m38 m43.7 m36.3 m42.1 m

Operating expense total

30.1 m32.6 m37.4 m38.4 m41.2 m47.5 m53 m46.1 m58.8 m

EBIT

(2.8 m)(985 k)3.3 m1.8 m5.1 m(2.3 m)(6.4 m)(20.9 m)(14.1 m)

EBIT margin, %

(6%)(2%)6%3%8%(3%)(9%)(31%)(20%)

Interest expense

(2.1 m)(2 m)(2 m)(1.9 m)(1.9 m)(1.9 m)(1.7 m)(1.6 m)(2.6 m)

Interest income

61 k134 k155 k177 k171 k252 k324 k346 k514 k

Pre tax profit

(5 m)(3 m)1.3 m47 k3.4 m(3.8 m)(7.9 m)(22.1 m)(19.8 m)

Income tax expense

(52 k)(39 k)(281 k)(32 k)(58 k)(36 k)(30 k)

Net Income

(16.5 m)(19.5 m)1.3 m1.3 m4.4 m(3.9 m)(11.8 m)(34 m)(19.9 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

12.5 m37.5 m57 m35.9 m

Accounts Receivable

14.6 m22.4 m25.9 m29.9 m

Inventories

15.6 m29.3 m6.1 m31.3 m

Current Assets

106.8 m214.3 m252.6 m243.1 m

Goodwill

10.3 m23.8 m30.9 m46.7 m

Total Assets

169.8 m326.1 m389.6 m391.5 m

Accounts Payable

3.1 m6.8 m8.7 m7.5 m

Current Liabilities

121.9 m140 m151.7 m44.8 m

Total Liabilities

172.5 m

Additional Paid-in Capital

337.6 m481.3 m526.7 m565.2 m

Retained Earnings

(296.4 m)(310.1 m)(308.3 m)(346.2 m)

Total Equity

41.2 m218.4 m219 m

Financial Leverage

4.1 x1.8 x1.8 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

108.2 m17.8 m40.9 m32.7 m30.5 m35 m25.3 m24.4 m109 m

Accounts Receivable

20.5 m20.5 m24.5 m24.3 m25.9 m25.9 m28.7 m26.8 m27.7 m

Inventories

19.2 m23.7 m36.3 m48.8 m56.1 m63.7 m60.9 m37.5 m30.3 m

Current Assets

208.9 m199.2 m248.6 m258 m235.4 m448 m

Goodwill

12.5 m22 m67.2 m77.8 m86.3 m32.8 m42.8 m44.7 m48.8 m

Total Assets

292.1 m305.4 m2.4 m2.3 m2.6 m391.2 m400.7 m381.2 m600 m

Accounts Payable

3.1 m7.7 m10.5 m4.6 m7.3 m9.4 m

Current Liabilities

129.5 m135.2 m136.5 m145.5 m145.4 m146.1 m150.4 m146.8 m45.6 m

Additional Paid-in Capital

460.9 m471 m36 k37 k37 k538.2 m548.3 m556.4 m637.1 m

Retained Earnings

(312.9 m)(315.9 m)492.9 m504.1 m514.8 m(312.1 m)(320.1 m)(342.3 m)(366.4 m)

Total Equity

(27 k)(29 k)226.2 m228.4 m214.1 m270.6 m

Financial Leverage

-83.4 x-89.5 x1.7 x1.8 x1.8 x2.2 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(63.9 m)(13.7 m)1.9 m(13.7 m)

Depreciation and Amortization

5.7 m

Accounts Receivable

(10 m)(7.8 m)(3.5 m)(7.8 m)

Inventories

(3.5 m)(14 m)(32 m)

Accounts Payable

10.2 m14.3 m9.9 m

Cash From Operating Activities

(43.2 m)25.5 m29 m26.6 m

Purchases of PP&E

(12.8 m)

Cash From Investing Activities

(43.6 m)(119.3 m)(20.2 m)(120.4 m)

Long-term Borrowings

(27.5 m)

Cash From Financing Activities

89.2 m118.9 m10.7 m118.9 m

Income Taxes Paid

34 k195 k34 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(16.5 m)(19.5 m)1.3 m1.3 m4.4 m(3.9 m)(11.8 m)(34 m)(19.9 m)

Depreciation and Amortization

4.9 m

Accounts Receivable

(6 m)(5.9 m)(2.1 m)(1.9 m)(3.6 m)(46 k)(2.8 m)(910 k)2.2 m

Inventories

(3.6 m)(8.1 m)(7 m)

Accounts Payable

5.2 m10.2 m(4.3 m)5 m2 m(6.2 m)(8.7 m)

Cash From Operating Activities

12.5 m493 k9.1 m12 m(3.1 m)4.4 m16.1 m6 k

Cash From Investing Activities

(21.6 m)(123.4 m)(1.2 m)(20.6 m)(27.5 m)(21.9 m)(41.5 m)(54.8 m)(143.8 m)

Long-term Borrowings

(117.7 m)

Cash From Financing Activities

113.8 m116.1 m4 m6.7 m8.5 m3 m5.4 m6.2 m216.9 m

Interest Paid

2.4 m

Income Taxes Paid

160159199142 k241 k253 k
USDY, 2017

Revenue/Employee

137.7 k

Financial Leverage

2.2 x

Pacira Pharmaceuticals Market Value History

Pacira Pharmaceuticals Job Categories

Traffic Overview of Pacira Pharmaceuticals

Pacira Pharmaceuticals Company Life and Culture

You may also be interested in